Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan.
We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18-89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. The 2-year overall survival (OS) rate for all patients was 51.9 %. By multivariate analysis, bone marrow involvement (P < 0.001) and ECOG >1 (P = 0.007) were independent adverse factors for OS. A simplified prognostic index efficiently stratified patients into the following three groups: 2-year OS rates 79.8 % (0 factor), 28.3 % (1 factor), and 10.2 % (2 factors) by using bone marrow involvement and ECOG >1 (P < 0.001). In conclusion, AITL patients were older and had poorer prognosis in Taiwan. Bone marrow involvement, EOCG >1, IPI >1 and PIT >1 had adverse impact on OS. The usefulness of this simplified prognostic index needs further validation.
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.|Graduate Institute of Clinical Medical Science, College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.
Hsiao-Wen
HW
Kao
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.
Tung-Liang
TL
Lin
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.|College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.
Lee-Yung
LY
Shih
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.|College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.
Po
P
Dunn
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.|College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.
Ming-Chung
MC
Kuo
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.
Yu-Shin
YS
Hung
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.
Jin-Hou
JH
Wu
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.|College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.
Tzung-Chih
TC
Tang
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.|College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.
Hung
H
Chang
College of Medicine, Chang Gung University, Taoyuan City, Taiwan, ROC.|Department of Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan, ROC.
Tseng-Tong
TT
Kuo
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC.
Che-Wei
CW
Ou
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, No. 5, Fuxing Street, Guishan District, Taoyuan City, 33305, Taiwan, ROC. dwang1415@gmail.com.
Po-Nan
PN
Wang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001855:Bone Marrow Diseases / Q000473:pathology; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D013624:Taiwan
D000970:Antineoplastic Agents
Angioimmunoblastic T cell lymphoma; Chemotherapy; Outcome; Prognostic index; Stem cell transplantation